Ebola successfully neutralized by latest generation polyclonal immunotherapy
(WorldNews Health)

Ebola successfully neutralized by latest generation polyclonal immunotherapy Promising new platform can rapidly respond to emerging infectious diseases Sioux Falls, SD, August 15, 2018 - SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided `100% protection against a lethal dose of the Ebola virus` in a recent animal study published in The Journal of Infectious Diseases. The study was conducted by the National Interagency Confederation for Biological Research and other collaborators including United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the...